Literature DB >> 30711926

MicroRNA-based Targeted Therapeutics in Pancreatic Cancer.

Nilgun Gurbuz1, Bulent Ozpolat2.   

Abstract

The discovery during the last decade of microRNAs (miRs, miRNA) and their role in regulating normal physiological processes as well as in the pathogenesis of human tumors has been a revolutionary development in molecular oncology. miRNAs activating or inhibiting oncogenic molecular pathways that are involved in tumorigenesis, cell progression, invasion, angiogenesis and metastasis are now considered of major impact in many cancer types. miRNA-based therapeutics that inhibit the levels of oncogenic miRNAs (oncomiRs) or elevate tumor suppressor miRs have enormous potential as molecular therapeutic targets. Thus, the development of new targeted cancer therapies based on miRNAs promise to revolutionize cancer treatment due to their increased efficacy compared to conventional chemoradiation-based therapies and hopefully to lower levels of adverse effects. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  clinical trial; miRNA; nanoparticle; pancreatic cancer; review; targeted therapy

Mesh:

Substances:

Year:  2019        PMID: 30711926     DOI: 10.21873/anticanres.13144

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Senescence-Associated miRNAs and Their Role in Pancreatic Cancer.

Authors:  Alexey Popov; Vaclav Mandys
Journal:  Pathol Oncol Res       Date:  2022-04-29       Impact factor: 2.874

Review 2.  Pathogenesis and Treatment of Pancreatic Cancer Related Pain.

Authors:  Ines Lohse; Shaun P Brothers
Journal:  Anticancer Res       Date:  2020-04       Impact factor: 2.480

Review 3.  Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology.

Authors:  Racheal G Akwii; Md S Sajib; Fatema T Zahra; Constantinos M Mikelis
Journal:  Cells       Date:  2019-05-17       Impact factor: 6.600

4.  A seven-miRNA expression-based prognostic signature and its corresponding potential competing endogenous RNA network in early pancreatic cancer.

Authors:  Xue Bai; Donglan Lu; Yan Lin; Yufeng Lv; Liusheng He
Journal:  Exp Ther Med       Date:  2019-07-03       Impact factor: 2.447

5.  Hypoxic pancreatic stellate cell-derived exosomal mirnas promote proliferation and invasion of pancreatic cancer through the PTEN/AKT pathway.

Authors:  Wenpeng Cao; Zhirui Zeng; Zhiwei He; Shan Lei
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

Review 6.  miRacle of microRNA-Driven Cancer Nanotherapeutics.

Authors:  Goknur Kara; Banu Arun; George A Calin; Bulent Ozpolat
Journal:  Cancers (Basel)       Date:  2022-08-06       Impact factor: 6.575

7.  MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K/Akt pathway.

Authors:  Xiwu Zhao; Jian Li; Dapeng Yu
Journal:  Int J Mol Med       Date:  2019-09-05       Impact factor: 5.314

8.  MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9.

Authors:  Yuzheng Xue; Tielong Wu; Yingyue Sheng; Yao Zhong; Benshun Hu; Chuanqing Bao
Journal:  Aging (Albany NY)       Date:  2021-07-27       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.